Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=122 A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
Heart Failure, Congestive · Edema
Primary: Body Weight — -0.53; -1.62; -1.35; -1.85 Kg — p=0.0074
Phase 2 N=104 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Cirrhosis
Primary: Body Weight (Amount of Change) — -0.68; -2.31; -1.88; -1.67 Kg — p=0.3167
Phase 1 N=47 A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)
Hypertension
Primary: Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2 — -7.9; 3.8 Ohms — p=0.001
Phase 2 N=20 Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema
Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
Phase 2 N=157 A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Cardiac Edema (CHF)
Primary: Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8 — -1.96; -1.74; -1.4; -1.84 kg
Phase 4 N=50 Lymphedema Study for Arm or Leg Lymphedema
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
N/A N=20 Cerebral Edema in Pediatric Diabetic Ketoacidosis
Diabetic Ketoacidosis
Primary: Cerebral Edema Measured by MR Imaging (Apparent Diffusion Coefficient) — 36; 48 mm^2/sec
N/A N=80 Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes
Edema
Primary: Cutaneous Water Content — -1.1; -.82; -0.99; -2.1 percentage change in dielectric constant — p=>0.05
Phase 2 N=54 Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
Lymphedema
Primary: Change in Skin Thickness of the Calf of the Most Affected Leg, Measured by Skinfold Calipers — -6.83; -7.75 mm
N/A N=186 Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia
Pre-eclampsia
Primary: Detection of Fluid in the Lungs — 2; 3 Participants — p=.162
Phase 3 N=110 A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Edema, Cardiac
Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001
Phase 2 N=43 A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
Carcinomatous Edema
Primary: Change in Body Weight From Baseline at Final IMP Administration — -0.69; -0.34; -1.13; 0.70 Kg
Phase 3 N=20 A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Cardiac Edema
Primary: Body Weight — -1.68; -2.14 Kg
Phase 2 N=10 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
Phase 2 N=259 EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Number of Participants That Were 2-level Composite (CR-PCSS and PR-PCSS) Responders During the Observation Phase — 19; 0; 16; 0 Participants
Phase 2 N=375 EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Percentage of Composite Responders of at Least 2-Level Improvement of Severity — 20; 3 Participants
Phase 3 N=599 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Cumulative Response Rate of 15 or More Letter Improvement — 0.101; 0.092; 0.045; 0.258 Kaplan-Meier Estimate
Phase 3 N=668 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 53; 48; 38 Number of Participants
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
N/A N=34 Vasculera in Participants With Lipedema
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
Phase 3 N=162 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
Cirrhosis
Primary: Body ｗeight — -1.95; -0.44 Kg — p=<0.0001
Phase 4 N=20 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters
Phase 3 N=262 Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
Macular Edema
Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 60; 31 Patients
Phase 4 N=71 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 6 — 51.90; 18.60 letters
N/A N=21 Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Phase 2 N=33 Hemodynamics and Extravascular Lung Water in Acute Lung Injury
Acute Lung Injury
Primary: The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water
Phase 2 N=150 A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
Edematous Fibrosclerotic Panniculopathy (EFP)
Primary: Investigator Global Assessment of Aesthetic Improvement — 0.7; 0.9; 1.1; 0.5 units on a scale
Phase 3 N=46 Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
Anti- VGF Inhibitor · Diabetic Macular Edema · Diabetic Retinopathy
Primary: Incidence of Ocular and Non-Ocular Adverse Events (AEs) — 10; 8 participants